NANJING, China, Feb. 4 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical Group , a leading manufacturer and supplier of branded generic pharmaceuticals and innovative anti-cancer pharmaceuticals in the rapidly growing China market, announced today that it intends to release its 2007 fourth quarter results on Tuesday, March 4, 2008 before the market opens in the United States. Simcere’s chief executive officer, Jinsheng Ren, and chief financial officer, Frank Zhigang Zhao, will host an earnings conference call to discuss the company’s 2007 fourth quarter results on Tuesday, March 4, at 8 a.m. EST (Tuesday, March 4, at 9 p.m. Beijing/Hong Kong time).
Please ask to be connected to Simcere’s Q4 2007 Earnings Call and provide the following passcode: 77061243. Simcere also will broadcast a live audio webcast of the conference call. The broadcast will be available by visiting the “Investor Relations” section of the company’s Web site at http://www.simcere.com .
Following the earnings conference call, an archive of the call will be available by dialing:
United States toll-free dial-in number: +1.888.286.8010
The passcode for replay participants is: 29676278. The telephone replay also will be archived on the “Investor Relations” section of the company’s web site at http://www.simcere.com for seven days following the earnings announcement.
About Simcere Pharmaceutical Group
Simcere Pharmaceutical Group is a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in the rapidly growing China market. In recent years, Simcere Pharmaceutical Group has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic anti- stroke medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. It currently manufactures and sells 35 pharmaceutical products including antibiotics, anti-cancer medication and anti-stroke medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com .
CONTACT: In China: Frank Zhigang Zhao, Chief Financial Officer of Simcere
Pharmaceutical Group, +86-25-8556 6666 ext. 8818, or
zhaozhigang@simcere.com; In Hong Kong: Joseph Lo Chi-Lun of Brunswick
Group, +852 3512 5033, or jlo@brunswickgroup.com; In the United States:
Michele Loguidice of Brunswick Group LLC, +1-212-333-3810, or
ir@simcere.com, all for Simcere Pharmaceutical Group
Web site: http://www.simcere.com/
